Publisher's Synopsis
Low-molecular-weight (LMW) heparins are increasingly used in the prevention and treatment of thromboembolic disease because, compared to unfractionated heparins, they show a higher benefit/risk ratio and better clinical convenience. This special issue reports the proceedings of a symposium which reviewed all the available data on the properties of these agents and their therapeutic applications. Several contributions present studies on the use of LMW heparins in the prophylaxis of venous thromboembolism after surgery and in nonsurgical situations, as well as in the treatment of established venous thrombosis. Arterial thrombosis as another potential indication for LMW heparins is discussed. Authoritative and up-to-date, this publication is essential reading for anyone dealing with thromboembolic disease from a pharmacological or a clinical point of view.
